- Home
- OKYO vs BYSI Comparison
OKYO vs BYSI Comparison
Compare OKYO & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- BYSI
- Stock Information
- Founded
- OKYO 2007
- BYSI 2010
- Country
- OKYO United Kingdom
- BYSI United States
- Employees
- OKYO N/A
- BYSI N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- BYSI Health Care
- Exchange
- OKYO Nasdaq
- BYSI Nasdaq
- Market Cap
- OKYO 97.8M
- BYSI 79.0M
- IPO Year
- OKYO 2022
- BYSI 2017
- Fundamental
- Price
- OKYO $2.22
- BYSI $2.05
- Analyst Decision
- OKYO Strong Buy
- BYSI
- Analyst Count
- OKYO 1
- BYSI 0
- Target Price
- OKYO $7.00
- BYSI N/A
- AVG Volume (30 Days)
- OKYO 136.7K
- BYSI 37.6K
- Earning Date
- OKYO 07-18-2025
- BYSI 11-12-2025
- Dividend Yield
- OKYO N/A
- BYSI N/A
- EPS Growth
- OKYO N/A
- BYSI N/A
- EPS
- OKYO N/A
- BYSI N/A
- Revenue
- OKYO N/A
- BYSI N/A
- Revenue This Year
- OKYO N/A
- BYSI N/A
- Revenue Next Year
- OKYO N/A
- BYSI N/A
- P/E Ratio
- OKYO N/A
- BYSI N/A
- Revenue Growth
- OKYO N/A
- BYSI N/A
- 52 Week Low
- OKYO $0.90
- BYSI $0.98
- 52 Week High
- OKYO $3.35
- BYSI $3.44
- Technical
- Relative Strength Index (RSI)
- OKYO 42.84
- BYSI 54.65
- Support Level
- OKYO $2.33
- BYSI $1.86
- Resistance Level
- OKYO $2.93
- BYSI $2.18
- Average True Range (ATR)
- OKYO 0.22
- BYSI 0.17
- MACD
- OKYO -0.05
- BYSI 0.01
- Stochastic Oscillator
- OKYO 10.46
- BYSI 57.24
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.